Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Abcam forecasts double digit revenue growth for full-year as it sees product growth across the board

The AIM-listed antibody supplier said it expected revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10%
Antibodies
Revenue from custom products and licensing also grew by 18% during the year

Abcam PLC (LON:ABC) said it expects double-digit growth in its full-year results following strong income growth across all of its product categories.

The AIM-listed antibody supplier said it expects revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10% underpinning the rise after all product categories continued to grow ahead of its market.

READ: Abcam raises revenue guidance after Roche deal

The firm added that revenue from custom products and licensing, which accounted for around 7% of total revenue, also grew by 18% during the year.

Abcam also said it expected margins to be in line with the previous year's figure of 70.1%, while margins for adjusted earnings before interest, taxes, depreciation and amortisation were forecast to be in line with expectations.

In a note to clients, analysts at City broker Numis upped their target price for the firm to 1,380p from 1,316p, citing that the strong growth forecasts could “indicate the emergence of a new fourth double-digit growth engine in the business”.

In lunchtime trading Thursday, Abcam shares were down 4.8% at 1,322p.

View full ABC profile View Profile

Abcam Timeline

Newswire
January 10 2017

Related Articles

Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use